We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

52 hedge funds and large institutions have $161M invested in VYNE Therapeutics in 2018 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 5 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 5

39% more capital invested

Capital invested by funds: $116M → $161M (+$44.7M)

33% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 12

8% more funds holding

Funds holding: 48 → 52 (+4)

0.12% more ownership

Funds ownership: 0.86% → 0.99% (+0.12%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
52
Holders Change
+4
Holders Change %
+8.33%
% of All Funds
1.19%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
16
Increased
18
Reduced
5
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$11.2M
2
First Manhattan
First Manhattan
New York
+$7.86M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.14M
4
O
OrbiMed
New York
+$4.05M
5
JP Morgan Chase
JP Morgan Chase
New York
+$4.02M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$10.1M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.08M
3
Millennium Management
Millennium Management
New York
-$1.74M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$231K
5
CWM
Cornerstone Wealth Management
Missouri
-$200K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$308K +$269K +435 New
Goldman Sachs
27
Goldman Sachs
New York
$288K +$127K +205 +101%
TD Asset Management
28
TD Asset Management
Ontario, Canada
$278K +$242K +392 New
Squarepoint
29
Squarepoint
New York
$273K +$238K +385 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$252K +$40.1K +65 +22%
TCM
31
Tekla Capital Management
Massachusetts
$244K +$212K +344 New
TCIM
32
TIAA CREF Investment Management
New York
$184K +$160K +259 New
ARTA
33
A.R.T. Advisors
New York
$179K -$115K -187 -43%
Two Sigma Advisers
34
Two Sigma Advisers
New York
$158K +$137K +222 New
TI
35
Trexquant Investment
Connecticut
$151K +$132K +214 New
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$143K +$40.8K +66 +49%
VF
37
Virtu Financial
New York
$126K +$110K +178 New
TA
38
Teachers Advisors
New York
$121K -$1.24K -2 -1%
AIG
39
American International Group
New York
$63K +$19.1K +31 +53%
Barclays
40
Barclays
United Kingdom
$37K +$27.2K +44 +489%
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
$34K – – –
Citigroup
42
Citigroup
New York
$26K +$11.7K +19 +106%
Wells Fargo
43
Wells Fargo
California
$15K +$6.17K +10 +91%
Legal & General Group
44
Legal & General Group
United Kingdom
$11K – – –
MAM
45
Meeder Asset Management
Ohio
$9K +$7.41K +12 New
PSC
46
Piper Sandler & Co
Minnesota
$9K +$7.41K +12 New
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$7K -$58K -94 -91%
AIP
48
Ameritas Investment Partners
Nebraska
$5K – – –
PNC Financial Services Group
49
PNC Financial Services Group
Pennsylvania
$2K – – –
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$1.99K – – –
1
2
3

VYNE Hedge Fund Activity: Q3 2018 in Review

52 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q3 2018, worth a combined $161M — up 39% from $116M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new VYNE positions and 12 closed out — a net gain of 4 holders — while 18 added to existing stakes and 5 trimmed.

The largest buyer was Great Point Partners, opening a new position worth an estimated $11.2M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $10.1M sold.

  • 52 institutional investors held VYNE Therapeutics (VYNE) as of Q3 2018, up from 48 in Q2 2018.
  • Funds reported $161M of VYNE Therapeutics stock for Q3 2018, up 39% quarter-over-quarter.
  • 16 funds opened new VYNE Therapeutics positions in Q3 2018 and 12 closed out, a net change of +4 holders.
  • The largest VYNE Therapeutics buyer in Q3 2018 was Great Point Partners, an estimated $11.2M added.
  • The largest VYNE Therapeutics seller in Q3 2018 was Perceptive Advisors, an estimated $10.1M sold.

Based on aggregated 13F filings for Q3 2018.